CURIGLIANO, GIUSEPPE
CURIGLIANO, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database
2026 C. Aristei, M. Tomatis, A. Ponti, L. Marotti, N.M.L. Battisti, K. Leung Cheung, O.J. Hartmann, I.T. Rubio, D. Santini, F. Sardanelli, E. Senkus, P. Van Dam, G. Curigliano
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
2026 N. Harbeck, S. Modi, L. Pusztai, S. Ohno, J. Wu, S. Kim, A. Yoshida, A. Fabi, X. Cao, R. Joseph, R. Li, B. Żurawski, S. Escrivá-de-Romaní, R. Meneguetti, A. Supavavej, S. Chen, Z. Liu, C. Kelly, G. Curigliano, W.F. Symmans, M. Gufran, J. Ke, A. Konpa, P. Herbolsheimer, J. Boileau
Locally advanced breast cancers: the EUSOMA experience
2026 P. Van Dam, M. Tomatis, A. Ponti, L. Marotti, J. Verhaegen, C. Aristei, M.J. Cardoso, K.L. Cheung, G. Curigliano, J. De Vries, D. Santini, F. Sardanelli, I.T. Rubio, C.A.P. Anghelone, A. Baldissera, E. Benozzi, M. Berlière, B. Bussels, K. Cagossi, N. Caldana, F. Caruso, C. Cedolini, F. Corsi, E. Despierre, L. Despini, B. Dullens, A.J. Esgueva, G. Fogazzi, L. Fortunato, J.L. Fougo, D. Generali, A. Gennari, M. Ghilli, P.F. Gouveia, S. Grossi, J. Heiman, R. Helfgott, A. Huscher, H. Loobuyck, M.E. Edith Lüthy, S. Marquette, G. Melucci, F. Piacentini, A. Prové, F. Riccardi, K. Rogowski, G. Romanucci, L. Rossi, C.R. Santos, S. Scomersi, G. Staelens, M. Vassilieff, V. Venizelos, P. Veronesi, C. Zamagni, D. Zanoni
Advancing oncology innovation under persistent constraints
2026 D. Trapani, G. Curigliano
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
2026 F. Ligorio, L. Provenzano, G. Fotia, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Mazzoli, F. Jacobs, G. Armani, C. Sposetti, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, L. Boldrini, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus
2026 C. De Angelis, D. De Biase, L. Gerratana, G. Arpino, G. Bianchini, I. Castellano, G. Curigliano, L. Del Mastro, A. Fabi, N. Fusco, A. Gennari, V. Guarneri, C. Zamagni, A. Zambelli, U. Malapelle, F. Puglisi
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial
2026 J. O'Shaughnessy, F. Bidard, P. Neven, M.L. Casalnuovo, P. Aftimos, C. Saura, N. Harbeck, L.A. Carey, G. Curigliano, J.A. Garcia-Saenz, M.F. Abad, L.D. Paula, Y.H. Park, O. Ozyilkan, M. Munoz, E. Barrett, S. Cao, A. Chawla, K.L. Jhaveri
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025
2026 E. Nicolò, F. Bertucci, H. Boussen, G. Curigliano, V. Fraser, L. Gerratana, S. Krishnamurthy, H.T. Le‐petross, B. Lim, F. Lynce, A. Lucci, S. Lucotti, M. Manai, S. Merajver, N. Missal, A. Nasrazadani, A. Soliman, C. Valenza, C. Van Berckelaer, S. Van Laere, W.A. Woodward, M. Cristofanilli, G. Devi
Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2− metastatic breast cancer
2026 A. Brufsky, R.M. Layman, X. Liu, B. Li, L. Mcroy, A. Cohen, M. Estevez, P. Cottu, M. Thill, G. Curigliano, H.S. Rugo
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
2026 G. Mazzoli, L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Fotia, M. De Monte, F. Ligorio, F. Jacobs, G. Armani, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, A.C. Schianca, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, G. the PALMARES-2 study, C. Vernieri
Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions
2026 J.D. Etessami, C. Valenza, A.W. Tolcher, P. Lorusso, G. Curigliano
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
2026 G. Corso, C. Andreon, C. La Vecchia, E.I. Bottazzoli, G. Abruzzese, K. Favilla, O. Citterio, E. Spoldi, S. Di Silvestre, A.M. De Scalzi, A. Polizzi, E. Meduri, D. Trapani, L. Nicosia, F. Pesapane, D. Bossi, E. Brogi, S. Shen, R. Mukhtar, C. Criscitiello, P. Veronesi, S. Gandini, F. Magnoni, G. Curigliano
Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)
2025 A. Rossi, A.G. Leone, M. Lambertini, E. Sperti, C. Cassani, A. Vetromile, S. Barni, A. De Giorgi, E.P. Preti, S. Secondino, N. Silvestris, R. Berardi, A. Brunello, G. Curigliano, N. La Verde, T.P. Latiano, F. Pietrantonio, M. Tiseo, M. Di Maio, F. Perrone, S. Cinieri, A. Fabi
Circulating tumor DNA: a biomarker for oncology drug development in phase I clinical trials?
2025 R. Asnaghi, R.M. Marsicano, V. Fuorivia, G. Malvezzi, J.D. Etessami, D. Izzo, C. Valenza, G. Curigliano, D. Trapani
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial
2025 X. Hu, G. Curigliano, K. Yonemori, A. Bardia, C.H. Barrios, J. Sohn, C. Lévy, W. Jacot, J. Tsurutani, A. Roborel De Climens, X. Wu, A. Andrzejuk-Ćwik, Z. Mbanya, R. Dent
Bridging gaps in breast cancer care: a Breast Cancer Care Quality Index to improve outcomes worldwide
2025 E. Cazap, B.O. Anderson, G. Curigliano, S. Sehdev, F. Cardoso, A.R. Gonzalez, E. Shash, C. Yip, A. Mattar, Y. Chavarri-Guerra, M. Mutebi, Y. Yin, J.V. Rocha, I. Lucibello, N. Srivastava
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers
2025 S. Hurvitz, M. Simonelli, R. Yarza, D. Berz, S. Kitano, G. Del Conte, D. Acosta Eyzaguirre, B.G. Doger De Speville Uribe, D. Maier, D. Erzen, S. Aykut Yazgili, G. Curigliano, T. Deng, M. Yan, Q. Zhang, X. Wang, I. Nakayama, K. Shitara
Cancer treatment paradigms in the precision medicine era
2025 V. Subbiah, G. Curigliano, J.K. Sicklick, S. Kato, K. Tasken, A. Medford, D.T. Rieke, H. Chen, A. Wahida, L. Buschhorn, D. Horgan, R. Kurzrock
Tearing down inequalities in the healthcare system across Europe: the BEACON project
2025 C. Koukoutzeli, G. Ferraris, V. Coppini, M.V. Ferrari, E. Fragale, D. Trapani, I. Minchella, R. Grasso, G. Curigliano, G. Pravettoni